Natco

Delhi HC dismisses Roche's plea, allows Natco to sell generic Risdiplam

The court upheld a previous order denying Roche's injunction plea, citing public interest and affordability in treatment for spinal muscular atrophy patients

Natco Pharma surges 5% after USFDA classifies Hyderabad facility as VAI

Natco Pharma stock was trading at ₹884.5, up 3.2 per cent compared to the previous session's close of ₹857.25 on the NSE

Stocks to watch on May 28: LIC, Natco Pharma, AstraZeneca India, Nalco

Stocks to watch on May 28: LIC reported a 15.6 per cent year on year (YoY) increase in standalone net premium income, reaching Rs 1.52 lakh crore in Q4FY24 compared to Rs 1.32 lakh crore

Natco Pharma to set up subsidiary in Indonesia with investment of $3 mn

Natco Pharma Ltd on Thursday said its board has approved setting up of a subsidiary in Indonesia with an investment of up to USD 3 million (nearly Rs 25 crore) for selling pharmaceutical products in that country. The new subsidiary -- PT. NATCO Lotus Farma -- will be a joint venture with Natco holding 51 per cent and the balance stake 49 per cent by PT. Mitra Medis Exim (MME), a part of Mitra Jaya Group, which is a 40 year old multi-diversified group, as the co-promoter, the company said in a regulatory filing. The company's board approved the proposal at its meeting held on Thursday. Natco will initially invest USD 1 million for a stake of 51 per cent as capital contribution and balance will be invested as and when the funds are required by the subsidiary, it added. PT. NATCO Lotus Farma will be engaged in selling pharmaceutical products in Indonesia, it added. MME is in the business of distribution for active pharmaceutical ingredients and excipients for end-users in Indonesia.

J&J, Momenta Pharma file patent infringement lawsuit against Natco, Mylan

Johnson & Johnson and Momenta Pharmaceuticals lawsuit alleges infringement of two old patents associated with 20mg/ml and 40mg/ml Glatiramer Acetate injection, Natco said in a regulatory filing.

Natco starts phase-3 trials of Molnupiravir capsules for Covid-19 treatment

Natco Pharma on Friday said it has initiated phase-III clinical trials of Molnupiravir capsules to evaluate its efficacy in treating patients with mild COVID-19.

Taiho Pharma moves US court against Natco for patent infringement

Taiho alleged that the Indian drug maker's proposed generic Lonsurf (trifluridine and tipiracil) will infringe the patent

Delhi HC rules in favour of Indian pharma manufacturers Natco and Alembic

The Delhi High Court on Wednesday allowed Indian drug manufacturers Natco Pharma and Alembic Pharmaceuticals to export Sorafinat and Rivaroxiban, generics of German pharma major Bayer's own cancer and blood thinning medicines. Bayer had initiated proceedings against the two Indian pharma companies to stop them from exporting the drug, which the defendants had claimed were being exported for purposes of experimentation and generation of valuable clinical trial data. Bayer had opposed this stance and argued that such exports did not meet the exceptions to patent infringement provided under Section 107A of the Indian Patents Act, 1970, as they violated conditions of compulsory licenses (Natco) and exceeded reasonable quantities (Alembic). Bayer had claimed that under the compulsory license provided to Natco, the company could only sell Sorafinat within India and that Alembic could not take benefit of the exception as they had exported over 90 kilograms of Rivaroxiban, worth around Rs 3 .